Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 950 GBX 4.17% Market Closed
Market Cap: 4.3B GBX
Have any thoughts about
Hikma Pharmaceuticals PLC?
Write Note

Relative Value

The Relative Value of one HIK stock under the Base Case scenario is 4 729.82 GBX. Compared to the current market price of 1 950 GBX, Hikma Pharmaceuticals PLC is Undervalued by 59%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HIK Relative Value
Base Case
4 729.82 GBX
Undervaluation 59%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
88
vs Industry
55
Median 3Y
1.9
Median 5Y
2.2
Industry
2.5
Forward
0
vs History
36
vs Industry
16
Median 3Y
19.7
Median 5Y
16.2
Industry
21.9
Forward
0.1
vs History
71
vs Industry
38
Median 3Y
8.9
Median 5Y
9.7
Industry
16.5
vs History
58
vs Industry
20
Median 3Y
20.9
Median 5Y
20.9
Industry
23.6
vs History
77
vs Industry
33
Median 3Y
2.4
Median 5Y
2.5
Industry
2.1
vs History
46
vs Industry
7
Median 3Y
31.3
Median 5Y
26
Industry
2.6
Forward
0.3
vs History
36
vs Industry
3
Median 3Y
65.5
Median 5Y
50.2
Industry
5.2
vs History
17
vs Industry
3
Median 3Y
102.3
Median 5Y
95.7
Industry
13.3
Forward
1.1
vs History
36
vs Industry
2
Median 3Y
151.7
Median 5Y
115.5
Industry
16.6
Forward
1.3
vs History
36
vs Industry
3
Median 3Y
160.3
Median 5Y
148.2
Industry
15.6
vs History
55
vs Industry
2
Median 3Y
259.9
Median 5Y
247
Industry
19.1
vs History
46
vs Industry
5
Median 3Y
23.2
Median 5Y
17.3
Industry
1.9

Multiples Across Competitors

HIK Competitors Multiples
Hikma Pharmaceuticals PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Hikma Pharmaceuticals PLC
LSE:HIK
4.3B GBP 1.8 19 111.7 151.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
UK
Hikma Pharmaceuticals PLC
LSE:HIK
Average P/E: 30.7
19
200%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top